Tech Company Financing Transactions
Resilience Bio Funding Round
Resilience Bio closed a $625 million Series D funding round on 6/6/2022. Investors included private investors.
Transaction Overview
Company Name
Announced On
6/6/2022
Transaction Type
Venture Equity
Amount
$625,000,000
Round
Series D
Investors
Proceeds Purpose
The company will use the funding to continue to invest in building its infrastructure network through strategic collaborations, acquisitions, organic growth and international expansion, and by developing innovative biomanufacturing technologies to ensure the medicines of today and tomorrow can be made quickly, safely and at scale.
Company Information
Company Status
Private & Independent
Industry
Enterprise IT
Mailing Address
9310 Athena Circle
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Resilience is changing the way medicine is made -- leveraging innovation to better serve scientific discovery, withstand disruptive events, and reach those in need.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Patrick Yang
Chief Executive Officer
Rahul Singhvi
Chief Scientific Officer
Richard Stoner
President
Sandy Mahatme
VP - General Counsel
Ori Solomon
VP - Manufacturing
James Miller
Browse more venture capital transactions:
Prev: 6/6/2022: GO1 venture capital transaction
Next: 6/6/2022: Orna venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC transactions reported here come from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs